KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma

Modern Pathology

Volumn 16, Issue 3, 2003, Pages 246-255

  Elder, E Edström ^a   Xu, D ^a   Hoog A ^a   Enberg, U ^a   Hou, M ^a   Pisa, P ^a   Gruber, A ^a   Larsson, C ^a   Backdahl M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

EMMPRIN; hTERT; Ki 67; MMP 2; Paraganglioma; Pheochromocytoma; Telomerase

Indexed keywords

GELATINASE A; KI 67 ANTIGEN; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD147; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; MALE; MATRIX METALLOPROTEINASE 2; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037341420     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000056982.07160.E3     Document Type: Article

References (42)

1. Tischler A. The adrenal medulla and extra-adrenal paraganglia. In: Kovacs K, Asa S, editors. Functional endocrine pathology. Oxford, United Kingdom: Blackwell Scientific; 1998. p. 550-95.
2. Lack EE. Tumours of the adrenal gland and extra-adrenal paraganglia. Washington, D.C.: Armed Forces Institute of Pathology; 1997.
3. Kenady DE, McGrath PC, Sloan DA, Schwartz RW. Diagnosis and management of pheochromocytoma. Curr Opin Oncol 1997;9:61-7.
4. Medeiros LJ, Wolf BC, Balogh K, Federman M. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 1985;16:580-9.
5. Solcia EKG, Sobin LH, editors. Histological typing of endocrine tumours. 2nd ed. Berlin: Springer; 2000.
6. Proye CA, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W. "The" pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 1994;18:467-72.
7. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg 1990;14:325-9.
8. Goldstein RE, O'Neill JA Jr, Holcomb GW III, Morgan WM 3rd, Neblett WW 3rd, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-64.
9. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001;10:677-85.
10. Kontogeorgos G, Kovacs K. Telomeres and telomerase in endocrine pathology. Endocrine 1998;9:133-8.
11. Saji M, Xydas S, Westra WH, Liang CK, Clark DP, Udelsman R, et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 1999;5:1483-9.
12. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
13. Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 1999;86:1583-9.
14. Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Mol Morphol 2000;8:267-74.
15. Ohji H, Sasagawa I, Iciyanagi O, Suzuki Y, Nakada T. Tumour angiogenesis and Ki-67 expression in phaeochromocytoma. Br J Urol Int 2001;87:381-5.
16. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum Pathol 1998;29:522-6.
17. van der Harst E, Bruining HA, Jaap Bonjer H, van der Ham F, Dinjens WN, Lamberts SW, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 2000;191:175-80.
18. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
19. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995;55:434-9.
20. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 2001;158:1921-8.
21. Kjellman M, Enberg U, Höög A, Larsson C, Holst M, Farnebo LO, et al. Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas. World J Surg 1999;23:237-42.
22. Dalberg K, Eriksson E, Enberg U, Kjellman M, Bäckdahl M. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 2000;24:334-40.
23. Zedenius J, Ståhle-Bäckdahl M, Enberg U, Grimelius L, Larsson C, Wallin G, et al. Stromal fibroblasts adjacent to invasive thyroid tumors: expression of gelatinase A but not stromelysin 3 mRNA. World J Surg 1996;20:101-6.
24. Xu D, Gruber A, Björkholm M, Peterson C, Pisa P. Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. Br J Cancer 1999;80:1156-61.
25. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br J Haematol 1998;102:1367-75.
26. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988;263:6579-87.
27. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999;53:679-83.
28. Edström Elder E, Hjelm Skog A-L, Höög A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol (in press).
29. Geoghegan JG, Emberton M, Bloom SR, Lynn JA. Changing trends in the management of phaeochromocytoma. Br J Surg 1998;85:117-20.
30. Jansson S, Tisell LE, Hansson G, Stenström G. Multiple neuroectodermal abnormalities in pheochromocytoma patients. World J Surg 1988;12:710-7.
31. Nativ O, Grant CS, Sheps SG, O'Fallon JR, Farrow GM, van Heerden JA, et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 1992;69:2683-7.
32. Heaney AP, O'Rourke D, Arthur K, Beatty OL, Russell CF, Sloan JM, et al. Flow cytometric analysis does not reliably differentiate benign from malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1996;44:233-8.
33. de Krijger RR, van der Harst E, van der Ham F, Stijnen T, Dinjens WN, Koper JW, et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 1999;188:51-5.
34. Castilla-Guerra L, Moreno AM, Fernandez-Moreno MC, Utrilla JC, Fernandez E, Galera-Davison H. Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas. Histopathology 1997;31:144-9.
35. Yoshimoto T, Naruse M, Zeng Z, Nishikawa T, Kasajima T, Toma H, et al. The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol 1998;159:247-55.
36. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 1989;7:1720-5.
37. Grouzmann E, Gicquel C, Plouin PF, Schlumberger M, Comoy E, Bohuon C. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas. Cancer 1990;66:1833-5.
38. Salmenkivi K, Arola J, Voutilainen R, Ilvesmaki V, Haglund C, Kahri AI, et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 2001;86:2231-5.
39. Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 1998;82:176-9.
40. Kinoshita H, Ogawa O, Mishina M, Oka H, Okumura K, Yamabe H, et al. Telomerase activity in adrenal cortical tumors and pheochromocytomas with reference to clinicopathologic features. Urol Res 1998;26:29-32.
41. Bamberger CM, Else T, Bamberger AM, Frilling A, Beil FU, Allolio B, et al. Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes 1999;107:272-5.
42. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.